In order to study human acute lung injury and pneumonia, it is important to develop animal models to mimic various pathological features of this disease. Here we have developed a mouse lung injury model by intra-tracheal injection of bacteria Pseudomonas aeruginosa (P. aeruginosa or PA). Using this model, we were able to show lung inflammation at the early phase of injury. In addition, alveolar epithelial barrier leakiness was observed by analyzing bronchoalveolar lavage (BAL); and alveolar cell death was observed by Tunel assay using tissue prepared from injured lungs. At a later phase following injury, we observed cell proliferation required for the repair process. The injury was resolved 7 days from the initiation of P. aeruginosa injection. This model mimics the sequential course of lung inflammation, injury and repair during pneumonia. This clinically relevant animal model is suitable for studying pathology, mechanism of repair, following acute lung injury, and also can be used to test potential therapeutic agents for this disease.
Introduction
Lungs are exposed to environmental pathogens and are susceptible to inflammation and injury [1] [2] [3] . During pathological conditions such as pneumonia or Adult Respiratory Distress Syndrome (ARDS), pathogens as well as inflammatory factors released by leukocytes induce injury and death of alveolar cells [1] [2] [3] . It is important to develop animal models of acute lung injury to facilitate the study of pathology of injury as well as mechanism of repair.
Currently, most people use hyperoxia and bleomycin induced mouse lung injury models 4 . However, the mechanisms of hyperoxia caused injury are not the same as most common lung injuries that occur during pneumonia or ARDS 5 . Bleomycin induced acute injury is rare in a clinical context 4 . Here we report a mouse lung injury model using intra-tracheal injection of P. aeruginosa 6, 7 . This model is clinically relevant, and mimics the processes that happen following pneumonia 8 .
As an opportunistic, nosocomial pathogen of immunocompromised individuals, P. aeruginosa typically infects the pulmonary tract, urinary tract, burns, wounds, and also causes other blood infections 6 . The bacteria release virulence factor exotoxin A, multiply and trigger immune responses 6 . Intra-trachael administration of P. aeruginosa reflects the situation in human exposure to the bacteria which cause pneumonia and the pathology is likely to be different from the recently reported influenza virus H1N1 induced lung injury model 9 . Since P. aeruginosa is an opportunistic pathogen, it is relatively safe to handle as compared to some of the more virulent pathogens. Here we used intra-tracheal injection to administer the bacteria because we observed that this method introduced more bacteria into the distal alveoli region of the lung compared with some other procedures such as using a catheter via mouth.
Compared with other acute lung injury models, the P. aeruginosa model described here is suitable for studying lung injury induced by bacteria and by excessive inflammation. Unlike other animal models that use P. aeruginosa to induce sepsis
Representative Results
Starting from 24 -72 hr post P. aeruginosa injection, increased cellularity was observed in lung sections (Figure 1A-D) . The lung started to recover from 96 hr post injury (Figure 1E ). At 7 days post P. aeruginosa, normal alveoli morphology was largely restored (Figure 1F) . Tunnel staining using lung sections prepared at 24 hr post P. aeruginosa showed cell death in alveoli cells (Figure 1G-I) . In order to study the repair process in this injury model, BrdU was injected into mice at 3 days post P. aeruginosa. Lungs were isolated at 5 hr post BrdU injection and processed for BrdU antibody staining. As shown in Figure 1J and K, significantly increased number of cells incorporated BrdU at 72 hr post P. aeruginosa administration indicating hyperproliferation.
To study the change in barrier permeability and inflammation post injury, bronchoalveolar lavage (BAL) fluid was collected at different time points post P. aeruginosa injection. The protein concentration in BAL was significantly increased at 48 hr post P. aeruginosa injection (Figure 2A) , indicating epithelial barrier leakiness. The cell numbers in BAL also increased significantly at 48 hr post P. aeruginosa injection (Figure 2B) , suggesting an inflammatory response. At 4 -5 days post P. aeruginosa injection, both the BAL protein level and cell number started to decrease suggesting recovery (Figure 2A,B) . Furthermore, lung lysate was collected at different points post P. aeruginosa administration and the level of macrophage inflammatory protein 2 (MIP2), a cytokine involved in neutrophil attraction (C) MIP-2 levels were measured using lung lysates isolated from control mice as well as mice at 48 hr and 96 hr post P. aeruginosa injection. Data were presented at mean ± SE, n ≥ 3. (D-F) Cells from BAL were centrifuged and fixed on glass slides and subjected to HEMA3 staining. A small number of monocytes were present in BAL of control mice (D). Large amount of neutrophils were present in BAL isolated at 48 hr post P. aeruginosa injection (E). By 96 hr post P. aeruginosa injection, there were a small number of monocytes in the BAL (F). Scale bar=10 µm, these results are representative of at least 5 independent experiments. This figure has been modified from Liu et al. 7 .
Please click here to view a larger version of this figure.
Discussion
The Pseudomonas mouse lung injury model that we describe here mimics the whole process of inflammation, lung injury, repair, and resolution that occur following acute lung injury or pneumonia. It has unique advantages comparing with several other injury models in that it is clinically relevant and relatively safe and easy to handle.
The critical step in the procedure is that the injection of bacteria solution needs to be very slow. If injection is too fast, the mice are likely to die by choke. After a successful injection, the mice usually show several deep breathes and gasp, which will help the bacteria particles get into the lung.
The strain we used was PA103 6 . One of the critical points of this model is that the titer of P. aeruginosa needs to be tightly controlled. Batch of P. aeruginosa from different source could show different degrees of inflammation and damage even when used at the same CFU. Therefore, it is recommended that every new batch of bacteria be tested for their causative effects (such as inflammation, cell proliferation, etc.), and accordingly adjust the number of CFU to be used. If inconsistency of results occurs by using refrigerated bacteria stock, one can use fresh stock obtained by growing bacteria from a fresh plate for each experiment. In addition, the growth phase of the bacteria and choice of media can also have an impact on the effect on the host response. Therefore, care should be taken to ensure that bacterial inoculations occur during the same phase of the bacterial growth cycle.
